Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $15.7 million.

  • Intellia Therapeutics' Other Accumulated Expenses fell 3540.39% to $15.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year decrease of 3540.39%. This contributed to the annual value of $26.4 million for FY2024, which is 382.69% down from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' Other Accumulated Expenses is $15.7 million, which was down 3540.39% from $22.9 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Other Accumulated Expenses peaked at $32.7 million during Q4 2022, and registered a low of $7.9 million during Q3 2021.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $24.2 million (2023), whereas its average is $22.3 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Other Accumulated Expenses soared by 28544.39% in 2022, and later plummeted by 3540.39% in 2025.
  • Intellia Therapeutics' Other Accumulated Expenses (Quarter) stood at $17.0 million in 2021, then soared by 92.5% to $32.7 million in 2022, then dropped by 16.13% to $27.4 million in 2023, then decreased by 3.83% to $26.4 million in 2024, then crashed by 40.4% to $15.7 million in 2025.
  • Its last three reported values are $15.7 million in Q3 2025, $22.9 million for Q2 2025, and $24.7 million during Q1 2025.